Arch Biopartners, Inc. · TSXV:ARCH

Arch Biopartners — Investor Presentation (November 2025)

18 slides from Arch Biopartners's investor presentation, November 2025

  1. Slide 1: New Drugs for Acute Kidney Injury and Chronic Kidney Disease

    TSXV: ARCH.V OTCQB: ACHFF.US New Drugs for Acute Kidney Injury and Chronic Kidney Disease November 2025 www.archbiopartners.com

  2. Slide 2: Notes about forward looking statements

    Notes about forward looking statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of our future performance, liquidity and capital resources, as well as the ongoing clinical development of our drug candidates

  3. Slide 3: Millions face acute and chronic kidney disease every year.

    Millions face acute and chronic kidney disease every year. Acute Kidney Injury (AKI) Chronic Kidney Disease (CKD) ■ Affects approximately 14–16 million ■ More than 800 million people globally, people each year in the U.S. and E.U.1, 2 with diabetic kidney disease as the ■ No approved treatments; pat

  4. Slide 4: Arch Biopartners is developing novel drugs for acute and chronic kidney diseases.

    Arch Biopartners is developing novel drugs for acute and chronic kidney diseases. Cardiac Surgery- Drug Induced Acute Chronic Kidney Associated Acute Kidney Injury (DI-AKI) Disease (CKD) Kidney Injury (CS-AKI) Cilastatin is in a Phase II Pre-clinical platform LSALT peptide is in a trial to prevent D

  5. Slide 5: LSALT peptide is in a Phase II trial to protect kidneys from CS-AKI.

    LSALT peptide is in a Phase II trial to protect kidneys from CS-AKI. Up to 30% of cardiac surgery (CS) patients on bypass machines experience acute kidney injury (AKI).3,4 ■ Over one million cardiac surgeries, ■ More information about the Phase II including bypass procedures, are CS-AKI Trial: Clini

  6. Slide 6: LSALT peptide targets Dipeptidase-1 (DPEP1).

    LSALT peptide targets Publication in CELL Dipeptidase-1 (DPEP1). A novel pathway to block kidney inflammation. Arch Scientists publication Watch LSALT peptide in Cell (2019): DPEP1 preventing inflammation: mediates neutrophil Kidney protected Inflammatory adhesion in the kidney, with LSALT White Blood

  7. Slide 7: Cilastatin: a repurposed DPEP1 inhibitor in a Phase II trial for drug-induced AKI.

    Cilastatin: a repurposed DPEP1 inhibitor in a Phase II trial for drug-induced AKI. Drug-induced AKI is a common complication of widely used antibiotics, chemotherapy, and other nephrotoxic drugs, with no approved treatments. The PONTiAK trial is testing cilastatin to The study is independently funde

  8. Slide 8: Repurposing cilastatin as a treatment for drug-induced AKI.

    Repurposing cilastatin as a Publication in NKF: Kidney Medicine treatment for drug-induced AKI. Cilastatin inhibits nephrotoxin uptake by kidney cells, an off-target effect that may prevent AKI caused by widely used antibiotics, chemotherapy drugs, and contrast agents used in medical imaging. Pre-cl

  9. Slide 9: Hundreds of millions are affected by chronic kidney disease (CKD) worldwide.

    Hundreds of millions are affected by chronic kidney disease (CKD) worldwide. Arch’s CKD program targets interleukin-32 (IL-32), a human cytokine directly implicated in kidney inflammation and diabetic kidney disease (DKD). ■ 800M people affected globally; Arch’s IL-32 strategy advances a 35–38M in th

  10. Slide 10: IL-32 as a novel driver of diabetic kidney disease.

    IL-32 as a novel driver of Abstract in JASN diabetic kidney disease. Interleukin-32 (IL-32) has been identified as a potential mediator of lipid droplet accumulation and chronic inflammation in kidney cells, key processes underlying diabetic kidney disease (DKD), the leading cause of kidney failure wo

  11. Slide 11: Arch's leadership in kidney therapeutics is protected by strong patents.

    Arch’s leadership in kidney therapeutics is protected by strong patents. LSALT peptide Cilastatin CKD Platform Composition and Method-of-use patents to Patents covering both method-of-use patents. repurpose cilastatin as a composition and Approval for the CS-AKI treatment to prevent AKI. method-of-u

  12. Slide 12: Next steps: Completing Phase II AKI trials and advancing the IL-32 CKD program.

    Next steps: Completing Phase II AKI trials and advancing the IL-32 CKD program. Arch’s programs target the leading causes of acute and chronic kidney injury, addressing millions of patients worldwide. The CS-AKI and PONTiAK Phase II trials Arch’s IL-32 CKD program highlights a target up to ~60% of a

  13. Slide 13: Investor Information

    Investor Information Latest news highlights, read and subscribe online. Read the latest news releases and download financial November 5, 2025 reports and filings (also at SEDAR+). Expands Phase II Cardiac Surgery-Associated AKI www.archbiopartners.com/investor-hub Trial to Include Royal Columbian Hosp

  14. Slide 14: Executive Management

    Executive Management Richard Muruve Andrew Bishop Dr. Daniel Muruve MD CEO, Director, Co-founder CFO, Director CSO, Co-Founder Mr. Muruve co-founded the Mr. Bishop is a Partner and A Professor in the Dept. of company with the Arch Co-Founder of Bingley Capital Medicine at the University of Inflammati

  15. Slide 15: A committed board and advisors.

    A committed board and advisors. Claude Allary, Director Farris Smith, Strategic Advisor Co-founder, partner of Bionest Consulting, President, Vimy Pharma, Former CFO, Leo Sanofi, Pfizer, Glaxo Pharma (North America), Novo Nordisk Canada. Richard Rossman, Director Patrick Vink, Strategic Advisor Gastro

  16. Slide 16: Contact us for more information.

    Contact us for more information. Contact us Latest news releases +1 647 428-7031 office archbiopartners.com/investor-hub/press-releases info@archbiopartners.com X (Twitter): About the company https://x.com/archbiopartners archbiopartners.com/about-us LinkedIN Investor information https://bit.ly/ArchBi

  17. Slide 17: Sources

    Sources 1. Sawhney, S., et al. Harmonization of epidemiology of acute kidney injury and acute kidney disease produces comparable findings across four geographic populations. Kidney International, Volume 101, Issue 6, 1271 - 1281. https://doi.org/10.1016/j.kint.2022.02.033 2. Pavkov M.E., et al. Trend

  18. Slide 18: Sources Cont.

    Sources Cont. 10. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022 Apr;12(1):7-11. Epub 2022 Mar 18. PMID: 35529086; PMCID: PMC9073222 https://doi.org/10.1016/j.kisu.2021.11.003 11. Francis, A., Harhay, M.N., Ong, A.C.M. et al. Chronic kidney disease

Arch Biopartners — Investor Presentation (November 2025) on 6ix